NYMOX PHARMACEUTICAL CORP
NYMXFDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
NX-1207
Benign Prostatic Hyperplasia (BPH)
NX-1207 2.5 mg
Prostate Cancer
2.5 mg NX-1207
Benign Prostatic Hyperplasia (BPH)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NX-1207 | Phase 3 | Benign Prostatic Hyperplasia (BPH) | - | - |
NX-1207 2.5 mg | Phase 2 | Prostate Cancer | - | - |
2.5 mg NX-1207 | Phase 2 | Benign Prostatic Hyperplasia (BPH) | - | - |
Frequently asked questions
What is in NYMOX PHARMACEUTICAL CORP's drug pipeline?→
CatalystAlert tracks 3 drug candidates in NYMOX PHARMACEUTICAL CORP's (NYMXF) pipeline across Phase 3, Phase 2. Its lead program is NX-1207 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NYMOX PHARMACEUTICAL CORP's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NYMOX PHARMACEUTICAL CORP (NYMXF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NYMXF biotech catalysts?→
Add NYMXF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NYMOX PHARMACEUTICAL CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.